Table 2.
Baseline Characteristics of the Subgroup of DLBCL Patients Treated With R-CHOP Who Had Genomic Classification Data Available for Analysis (N = 264).
| Variable | Proportion |
|---|---|
| ECOG > 2 | 3.41% |
| IPI > 2 | 43.56% |
| Raised LDH | 61.36% |
| Ann Arbor stage > II | 62.50% |
| Median age | 64.85% y |
| Number of extranodal > 1 | 17.80% |
| ABC subtype | 28.79% |
| GCB subtype | 46.59% |
| Unclassified subtype | 18.56% |
| MHG subtype | 6.06% |
| Lacy et al13 Akaike information criterion clusterization | BCL2: 21.97% |
| MYD88: 14.39% | |
| Unclassified: 25.00% | |
| NOTCH2: 18.94% | |
| SCOS1/SGK1: 10.61% | |
| TET2/SGK1: 9.09% | |
| Modified Lay et al13 Akaike information criterion clusterization | BCL2: 20.08% |
| BCL2-MYC: 1.89% | |
| MYD88: 14.39% | |
| Unclassified: 22.73% | |
| NOTCH1: 3.41% | |
| NOTCH2: 18.18% | |
| SCOS1/SGK1: 10.61% | |
| LymphGen classification | BN2: 9.85% |
| BN2/N1: 0.38% | |
| EZB: 23.86% | |
| EZB/ST2: 1.14% | |
| MCD: 7.95% | |
| MCD/ST2: 0.38% | |
| N1: 3.03% | |
| Unclassified: 45.83% | |
| ST2: 7.58% | |
| Modified LymphGen classification | BN2: 9.85% |
| BN2/N1: 0.38% | |
| EZB: 22.35% | |
| EZB-MYC: 1.52% | |
| EZB/ST2: 1.14% | |
| MCD: 7.95% | |
| MCD/ST2: 0.38% | |
| N1: 3.03% | |
| Unclassified: 45.83% | |
| ST2: 7.58% |
ABC = activated B-cell–like; DLBCL = diffuse large B-cell lymphoma; ECOG = Eastern Cooperative Oncology Group; IPI = International Prognostic Index; LDH = lactate dehydrogenase; MHG = molecular high-grade; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.